Phosphodiesterase 11 (PDE11) is the latest isoform of the phosphodiesterase family to be identified. Interest in PDE11 has increased recently because tadalafil, an oral phosphodiesterase 5 inhibitor, cross reacts with PDE11. The function of PDE11 remains largely unknown, but growing evidence points to a possible role in male reproduction. The published literature on PDE11 structure, function and expression is reviewed.
Introduction
Introduction of orally administered phosphodiesterase-5 (PDE5) inhibitors revolutionized the treatment of erectile dysfunction in the past decade. 1 Of the 11 known phosphodiesterases (PDEs), PDE5 has been the focus of much attention because it is the protein target of these inhibitors. Sildenafil was the first PDE5 inhibitor to be marketed followed by vardenafil and tadalafil. All three compounds inhibit the catalytic activity of PDE5, thereby preventing the degradation of intracellular cGMP. In turn, cGMP activates cGMP-dependent protein kinase, which phosphorylates a number of intracellular proteins resulting in decreased intracellular calcium concentration and leading to penile smooth muscle relaxation, vasodilatation, and subsequently, penile erection. Recently, there has been an increased interest in PDE11 because tadalafil, one of the newer PDE5 inhibitors approved for treatment of ED, crossreacts with PDE11. [2] [3] [4] [5] [6] The expression and function of PDE11 are still poorly understood, and this present review will summarize the current state of knowledge regarding PDE11 structure, function and distribution. Emphasis will be placed on the possible role of PDE11 in spermatogenesis and potential effects, if any, of tadalafil on it.
Overview of PDEs
Mammalian PDEs are divided into 11 families. 1, 6 Some families (PDE1, PDE3, PDE4, PDE7 and PDE8) are products of multiple genes (multigene), whereas others derive from a single gene (unigene) ( Table 1) . Thus, the human genome contains 21 known genes coding for PDEs. Variations in splicing and alternate initiation sites create more variety in each family, with a total number of 53 isoenzymes identified so far. 6, 7 All PDEs share a highly conserved catalytic domain near the carboxyl-terminus, 1 including 11 invariant amino acids in the active site. 8 Minor variations in the catalytic domain are believed to be responsible for the different selectivities towards cAMP or cGMP substrate and various inhibitors (Table 1) . 8 More substantial variation exists in the N-terminus part, where most of the regulatory domains reside. 1, 9 In the case of PDE11, there is a single gene in the family (PDE11A according to standard nomenclature) with four splicing variants (PDE11A1, PDE11A2, PDE11A3 and PDE11A4). This appears to be the case in all mammalian species studied so far (human, rat and mouse).
genome sequence is now available, it appears to be the last. The first published report of PDE11A was by Fawcett et al., 13 who obtained a partial sequence of PDE11A from a commercially available expressed sequence tag (EST) database based on homology with other mammalian PDEs. These investigators then used the PDE11A partial sequence to identify the PDE11A gene from a human skeletal muscle cDNA library. Soon after, the same group cloned PDE11A2 and PDE11A3 cDNAs from a human testis library. 12 Almost simultaneously, Yuasa et al.
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cloned the A3 and A4 isoforms of PDE11A by PCR with degenerate primers from the conserved catalytic domain of other PDEs, using a human multitissue cDNA library template. No other variants of human PDE11A have since been reported.
Gene structure of PDE11A
Among the mammalian superfamily of PDEs, PDE11 is phylogenetically related to the other GAF- 15 for a review). PDE11 most closely resembles PDE5 by sequence, with 50% identity and 70% similarity in the catalytic domain. 13 In humans, the PDE11 subfamily consists of a single gene, which has been localized to chromosome 2q31 by fluorescent in situ hybridization.
14 This was later confirmed by the Human Genome Project complete sequence. The gene spans a long stretch of DNA (4300 kb) and is spread over more than 20 exons (Figure 1 ). Alternate transcription initiation sites and alternate splicing are responsible for the generation of the four isoforms of PDE11A ( Figure 1) . 12, 14 The gene structure of PDE11A variants is detailed in Figure 1 . All four variants contain exons 8-23, which comprise the C-terminus of the protein with the catalytic domain. At the 5 0 end, however, the isoforms differ significantly. Omori's group 10, 14 identified three distinct transcription initiation sites for PDE11A1, PDE11A3 and PDE11A4, under the control of three different promoters. The promoters for A1 and A3 have canonical TATA motifs, whereas that for A4 is TATA-less but has a GC-rich region with a CCAAT box and Sp-1 binding site. It is speculated that these differences in promoters are responsible for the different patterns of tissue distribution exhibited by the various isoforms. 14 Sequence analysis of the upstream gene region demonstrated the presence of SRY and Sox-5 motifs. This hints at a potential role for PDE11A expression in testicular development. However, no functional studies of the PDE11A promoter have been published to date.
Alternate splicing is responsible for further variation in the PDE11 family. PDE11A1, the shortest form, does not include exons 1-6. Thus, it lacks the first GAF domain, and only includes a part of the second GAF. PDE11A2 and PDE11A3 are slightly longer, including the entire second GAF and parts of the first GAF domain, 10, 12, 14 whereas the longest form, PDE11A4, includes both domains in addition to two phosphorylation sites in the N-terminus part. 10 
Biochemical characteristics of PDE11A
PDE11A is a dual-substrate PDE, acting on both cAMP and cGMP. Most studies report similar Phosphorylation site * * * * * Figure 1 Gene structure of HSPDE11A (Homo sapiens PDE11A) and its four known variants. Gene structure is based on Yuasa et al.
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Exon numbers follow Yuasa et al., 14 in contrast to GeneBank that lists the 20 exons of PDE11A4 only. The 5 0 -most exon(s) of PDE11A2 have not been studied. 12 Sizes of the cDNA (in bp) and the predicted molecular weight (in kDa) of the open-reading frame protein are shown.
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A Makhlouf et al affinities (K m ) for both substrates (Table 2) . However, there have been slight discrepancies in the reported V max ratio for the breakdown of cAMP vs cGMP. Beavo's group found a V max ratio close to 1 in PDE11A1, PDE11A2 and PDE11A3, 12,13 whereas others reported a higher velocity for cAMP, 10 especially for the PDE11A4 isoform. 5 The consensus remains, however, that at physiologic concentrations, PDE11 is capable of degrading both cGMP and cAMP. 6, 16 The regulation of PDE11 function is very poorly understood. Like other GAF-containing PDEs, PDE11A4 has two GAF domains located in tandem near the N-terminal. 12, 14 In PDE5, binding of cGMP to GAF a, and perhaps to GAF b, enhances the rate of phosphorylation of the enzyme by cAK (cAMPdependent protein kinase) or cGK (cGMP-dependent protein kinase). 17 Binding of cGMP to the GAF a site has also been shown to increase the catalytic activity of PDE5 directly, without requiring phosphorylation of the enzyme. 18, 19 However, similar allosteric control of PDE11A4 could not be demonstrated to date. 5, 13, 14 Nevertheless, it is believed that PDE11A4 is subject to physiologic regulation. Two putative phosphorylation sites have been identified by Yuasa et al.
14 at Ser-117 and Ser-162 (marked by asterisks in Figure 1 ). In vitro, these residues were found to be phosphorylated by both cAK and cGK. However, whether these sites are phosphorylated in intact tissues and the in vivo role of this phosphorylation have yet to be elucidated. Several inhibitors of PDE11 have been identified and tested. The non-selective inhibitors IBMX, zaprinast and dipyridamole have all been documented to inhibit PDE11 (Table 2) . Furthermore, the PDE5-selective inhibitor tadalafil cross-reacts with PDE11 (see below for more discussion). 2, 3, 5 This is not surprising given the sequence similarity between PDE11 and PDE5. In fact, it appears that as PDE5 inhibitor variants are modified to react less and less with PDE6, they gain in PDE11 reactivity. 4 Unfortunately, there are no PDE11-specific inhibitors available as of this writing, 16 and this has presented a hurdle in the study of the physiological role of PDE11.
As tadalafil is widely used to treat erectile dysfunction, its effects on PDE11 deserve special mention. Tadalafil is selective for PDE5, but it crossreacts with PDE11 with reported IC 50 values of 37 4 and 73 nM 5 for PDE11A1 and PDE11A4, respectively. Tadalafil fold-selectivity for PDE5 over recombinant PDE11A1 was initially reported as 5 3 Fawcett et al.
Yuasa et al.
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RNPDE11A1t 2 A greater fold-selectivity (B40-fold) was reported for the longest isoform, PDE11A4. 5 The difference between these values for fold-selectivity could be owing to the isoform of PDE11 tested, variation in preparation of the proteins or to differences in assay conditions. Even with a 40-fold selectivity, some authors argue that clinical effects of tadalafil on PDE11 cannot be excluded. 20 In contrast to tadalafil, fold-selectivity of PDE5 vs PDE11 isoforms for sildenafil or vardenafil have been reported as 1500-and 640-fold for PDE5/PDE11A1 2 and 1000-and 9300-fold for PDE5/PDE11A4. 5 Expression and tissue distribution of PDE11A
The tissue distribution of PDE11A remains a topic of active study and some controversy. 16, 21, 22 The initial reports of PDE11A [11] [12] [13] found evidence for PDE11 expression in skeletal muscle, prostate, testis and salivary glands. Several studies since then have supported and sometimes contradicted these findings. A summary of all studies published to date on the expression of PDE11 is presented in Table 3 . Unfortunately, interpretation of these studies is rendered difficult because of differences in the species (human, rat or mouse) and isoforms (PDE11A1, PDE11A2, PDE11A3 or PDE11A4) studied. Furthermore, some studies investigated mRNA presence, whereas others reported protein expression, making direct comparisons difficult.
The presence of PDE11 in the prostate is the bestdocumented aspect of all the summarized studies. In fact, prostatic expression of PDE11 mRNA and/or protein was detected in every published study that included prostate specimens. 10, 11, 13, 21, 22, 25 However, some discrepancy exists in the literature as to which PDE11 isoform is present in the prostate. The two initial reports identifying PDE11 reported the presence of the longest transcript (10 kb) on Northern blots of prostatic RNA, whereas other tissues had shorter transcripts. 10, 13 Using specific primers, Yuasa et al. 10 identified this transcript as PDE11A4, and the view that PDE11A4 is expressed in the prostate, whereas PDE11A3 was restricted to the testis gained acceptance. 20 However, the same group later found that, in the rat, PDE11A4 is not expressed in the prostate. 11 Two studies found the major protein band detected in the prostate (56 kDa 13 and 70 kDa 22 ) to be too small for the expected weight of PDE11A4 (104 kDa). Still, a band of the right size (100-105 kDa) was seen in studies from at least two different labs with three different antibodies. 21, 22 Thus, the weight of the evidence clearly argues for the presence of PDE11A4 in human prostate, with other isoforms probably expressed as well. The location of the PDE11 signal was localized to the glandular epithelium by immunohistochemistry studies. 21, 22 The expression of PDE11 in the testis is somewhat more debatable. Seven studies from at least three different labs found PDE11 expression in the testis, whereas one recent study failed to detect it 21 (Table 3) . Most, but not all, evidence points to PD11A3 as the major testicular isoform. This finding was demonstrated in the case of mRNA using A3-specific PCR in both rats and humans. 10, 11 This result agrees with Western blot findings from two groups who found an approximately 75 kDa band in testicular extracts, which is close to the predicted size of PDE11A3. 16, 22 Unfortunately, both groups used the same commercial antibody, and in one of the two studies, a heavier band (100 kDa) had a stronger signal. 22 Furthermore, another group, using two monoclonal antibodies, failed to detect any PDE11 expression in the testis altogether. 21 These discrepancies could be owing to differences in antibody and/or assay sensitivity and specificity. We should note that the group that detected testicular PDE11 used 100 mg per Western blot lane and found PDE11 in a wide array of tissues. 22 In contrast, the investigators who reported no testicular expression of PDE11 loaded only 20 mg per lane and failed to detect it in the majority of tissues they examined. 21 Finally, studies using immunohistochemistry have localized the PDE11 signal to the germinal epithelium in the seminiferous tubules and to Leydig interstitial cells as well as spermatozoa. 22, 23, 25 The expression of PDE11 in tissues other than prostate and testis has been documented but not studied extensively. 10, 13, [22] [23] [24] Immunohistochemistry detected PDE11 in the smooth muscle of corpora cavernosa, 24 in vascular endothelium and smooth muscle, 22 in acidophils and lactotrophs of the anterior pituitary 23 and in parasympathetic ganglia of the heart. 21 Whether the presence of PDE11 in these tissues is of any physiological significance remains to be established.
Potential role of PDE11 in male reproduction
Although PDE11 was identified almost 6 years ago, very little is known about its physiologic function. Advances in this regard have been hampered by the absence of a specific inhibitor and by the lack of a clear pattern of PDE11 tissue expression. The recent creation of a mouse PDE11 À/À knockout strain, 25 however, holds some promise to identify the role of PDE11 in body functions. In addition, the widespread use of the PDE5 inhibitor tadalafil, which cross-reacts with PDE11, has hinted at a potential role for PDE11 in spermatogenesis and sperm capacitation in select patients with pre-existing fertility problems. 26 
Phosphodiesterase 11
A Makhlouf et al Spermatogenesis refers to the differentiation of spermatogonia into spermatids through the first and second meiotic divisions. There is ample evidence that this process is regulated through a cAMPdependent mechanism. First, adenylyl cyclase expression has been documented in spermatogonia, and it peaks during early meiosis. 27 Second, CREM (cAMP-responsive element) is a transcription factor that binds cAMP and promotes the transcription of several genes involved in spermatogenesis. Knockout mice deficient in CREM are infertile because of an arrest in spermatogenesis. 28 This can be reversed by implantation of wild-type spermatogonia, indicating that the defect is specific to the spermatogonia and not a systemic hormonal problem. 28 Given that PDEs regulate cAMP levels through its degradation, it stands to reason that they play a role in regulating spermatogenesis. However, it should be stressed that many PDEs are expressed in cells of the spermatogenic pathway, 16 and assigning a role to PDE11 in particular, at least in humans, is not warranted by the evidence so far.
Another area where PDE11 is suspected of playing a physiological role is in sperm capacitation. Sperm exiting the epididymis are incapable of fertilization until they undergo capacitation in the female genital tract. 29 Several factors influence capacitation, including factors secreted by the prostate. 30 The mechanism of capacitation is also cAMP dependent. 25 Several cytokines cause release of cAMP, which in turn causes an influx of calcium into the spermatozoon triggering capacitation. 25 By keeping cAMP levels low, PDEs are believed to prevent premature capacitation. 25 Two lines of evidence suggest the involvement of PDE11 in spermatogenesis and capacitation: animal studies and clinical trials with tadalafil, 26, 31 and the PDE11 knockout mouse model. 25 Daily administration of high doses of tadalafil (410 mg/kg/day) to beagle dogs was shown to cause atrophy of the germinal epithelium in 20-100% of animals with subsequent oligospermia in 40-75%.
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This effect was non-reversible upon drug cessation, suggesting damage to the germinal stem cell population. Whether this effect is owing to PDE11 inhibition or to another non-specific effect of tadalafil remains unknown. Interestingly, this negative effect on spermatogenesis was not observed when mice were given similarly high doses of the medication. 31, 32 It can be speculated that these differences are owing to species-specific patterns of PDE11 expression. Unfortunately, there are no published studies on PDE11 expression in canine testis.
Clinical studies of the effect of tadalafil on spermatogenesis in humans have yielded mixed results. In a double-blind cross-over study, Pomara et al. 26 found that acute tadalafil administration was associated with a statistically significant decrease in sperm straight line velocity in a group of 16 males who were less than 40 years old with a history of Studies are sorted by chronological order of publication. In 'result' column, the notation A1, A2, A3 or A4 refers to putative identification of the detected signal with PDE11A1, PDE11A2, PDE11A3 and PDE11A4, respectively. See text for further discussion. Amino-acid locations in the antibody column correspond to the PDE11A1 isoform sequence.
a Both abstracts 23, 24 refer to the antibody by name only (EPH3). We identified this with the similarly named anti-serum in Fawcett et al., 13 which was raised against a peptide spanning residues 410-424.
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A Makhlouf et al infertility. It is unknown whether the inhibition of PDE11 is the mechanism behind the observation or whether the changes in the parameters will translate to impact clinical fertility rates. In a larger 6-month, double-blind, placebo-controlled study, Hellstrom et al. 33 looked at the effects of 10 or 20 mg of tadalafil on semen parameters and reproductive hormones in 421 men older than 45 without a history of infertility. Inclusion criteria included a sperm concentration of 420 million, 50% sperm motility and 50% normal sperm morphology. Those with a history of infertility or abnormal hormone profile were excluded. The study found that in men older than 44, tadalafil had no significant affect on sperm concentration, morphology or motility nor had any affect on investigated hormone levels of testosterone, LH or FSH. It can be surmised that the affect of PDE11 inhibition, if any, by this medication was not detected or significant. Any potential effect of long-term tadalafil use on fertility parameters in men with a history of infertility or younger than age 45 years, however, remains unproven.
PDE11 À/À knockout mice were recently described by Wayman et al. 25 Knockout mice were found to be overall phenotypically normal without any gross or lethal abnormalities. However, a small but measurable decrease in sperm concentration of ejaculated sperm from 29.3 to 23.8 million/cm 3 was detected. This difference was accentuated by a slight increase in necrospermia in the PDE À/À knockout (45% viable sperm in PDE À/À vs 56% in wild type). In addition, pre-ejaculated sperm from knockout mice showed a 53% increase in the capacitated fraction, suggesting premature capacitation. However, it should be stressed that the knockout mice had fertility rates similar to those of wild-type mice, and were able to reproduce without difficulty. This suggests that redundant mechanisms, such as other PDE isoforms, may have mitigated the absence of PDE11.
Future directions
Most of the work on PDE11's function has focused on spermatogenesis. However, recall that the prostate is the site most consistently associated with PDE11 expression. It is possible that changes in sperm function seen with inhibitors of PDE11 are owing to changes in the contribution of the prostate to the seminal fluid, a contribution known to contain factors required for sperm capacitation. 30 Another area of research is idiopathic infertility owing to asthenospermia. One notable difference between studies showing no deleterious effect of tadalafil vs those showing changes in sperm parameters is that the patients studied in the former were normal fertile volunteers, whereas the latter consisted of infertility clinic patients. 26, 33 This raises the possibility that infertile men may have a different response to PDE11 inhibition. However, no studies to date have investigated PDE11 activity in infertile males, and the possibility of PDE11 malfunction underlying cases of infertility remains purely speculative.
In conclusion, we have summarized what is known about PDE11 structure, expression and function so far. Clearly new studies are needed to further our understanding of this PDE family.
